Focus on Protein Kinases for
Drug Development

ProQinase GmbH is a contract research organization (CRO) which provides an Integrated Protein Kinase Technology Platform for preclinical drug development of protein kinase inhibitors in oncology and other therapeutic areas: More than 164 in-house produced recombinant protein kinases are offered for sale and more than 250 kinases are available for in vitro kinase assay services (HTS, selectivity profiling and IC50 determination). Hits derived from in vitro kinase assays can be characterized at ProQinase in cellular phosphorylation assays and in a cellular angiogenesis assay. 

For further evaluation of lead compounds ProQinase offers various in vivo assays including subcutaneous xenograft and orthotopic tumor models, and an unique angiogenesis assay. ProQinase´s drug  development service portfolio is completed by a clinical biomarker assay service for determination of different biomarker proteins in serum or plasma samples derived from clinical trials.